Gritstone Oncology, Inc. (GRTS) News
Filter GRTS News Items
GRTS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GRTS News Highlights
- GRTS's 30 day story count now stands at 2.
- Over the past 6 days, the trend for GRTS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BIO and DEC are the most mentioned tickers in articles about GRTS.
Latest GRTS News From Around the Web
Below are the latest news stories about GRITSTONE BIO INC that investors may wish to consider to help them evaluate GRTS as an investment opportunity.
Forecast: Analysts Think Gritstone bio, Inc.'s (NASDAQ:GRTS) Business Prospects Have Improved DrasticallyCelebrations may be in order for Gritstone bio, Inc. ( NASDAQ:GRTS ) shareholders, with the analysts delivering a... |
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)EMERYVILLE, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted four employees nonqualified stock options to purchase an aggregate of 42,000 shares of its common stock with an exercise price of $1.53, which is equal to the closing price of Gritstone’s common stock on December 1, 2023, th |
Gritstone bio to Participate in Upcoming Investor ConferencesEMERYVILLE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conferences: 6th Annual Evercore ISI HealthCONx Conference (Fireside Chat)Presentation Date and Time: Wednesday, November 29, 2023 at 10:00am ETSpeaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive OfficerLocation: |
Gritstone Bio Inc (GRTS) Reports Q3 2023 Financial Results and Progress in Vaccine DevelopmentAdvancements in COVID-19 and Cancer Vaccine Programs Amid Increased R&D Spending |
Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates-- BARDA contract and IDWeek presentations position Gritstone’s self-amplifying mRNA (samRNA) as a leading next-generation approach to COVID-19 prevention; preparations underway for Phase 2b head-to-head study evaluating samRNA candidate versus an approved COVID-19 vaccine -- -- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating Gritstone’s personalized cancer vaccine (PCV), GRANITE, in first-line metastatic, microsatellite stable colorectal cancer (MSS-CRC) remain expected in 1 |
Genevant Sciences LNP Technology Used in samRNA Covid-19 Vaccine Candidate Behind Gritstone bio’s BARDA AwardVANCOUVER, British Columbia and BASEL, Switzerland, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, today announced the use of its LNP technology in Gritstone bio’s (Nasdaq: GRTS) self-amplifying mRNA (samRNA) vaccine candidate against COVID-19 in its CORAL program. Gritstone was recently awarded a contract by the Biomedical Advanced Research and Developme |
Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine-- High neutralizing antibody (nAb) responses sustained through at least 12 months, highlighting potential for durable clinical protection -- -- T cell responses to Spike plus other viral targets observed in all Phase 1 studies, demonstrating broad and potentially variant-proof immune response -- -- Over 300 subjects dosed to date across Phase 1 studies; vaccine tolerability appears comparable to approved COVID-19 vaccines -- -- Head-to-head Phase 2b study evaluating Gritstone’s self-amplifying |
retail investors who own 43% along with institutions invested in Gritstone bio, Inc. (NASDAQ:GRTS) saw increase in their holdings value last weekKey Insights Gritstone bio's significant retail investors ownership suggests that the key decisions are influenced by... |
Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced results from all three (3) Phase 1 studies evaluating its self-amplifying mRNA (samRNA) vaccine candidates against COVID-19 (part of the company’s CORAL program) are to be presented at IDWeek 2023, occurring October 11-15, 2023, in Boston, MA. Last week, Gritstone bio announced a contract with the Bio |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're checking out the biggest pre-market stock movers worth watching on Friday with a dive into all of the latest market stories! |